Thursday, May 22, 2025

5:30 PM-8:30 PM ET

Acute Leukemia & Myeloid Malignancies CME/CE Rounds
DoubleTree by Hilton Philadelphia Center City
Ormandy Ballroom
237 South Broad Street 
Philadelphia, PA 19107
 
*LLS will cover self-parking at the DoubleTree for practicing healthcare professionals only, upon submission of your completed evaluation and feedback form.
 
*Only one (1) person per medical technology/pharmaceutical company may register and attend the Rounds. A corporate email address is required.

Agenda

5:30 PM – Dinner and Networking
6:30 PM – Welcome and Overview of Program
Catherine Lai
6:40 PM – Overview of LLS Resources
Ruby Nava-Ramos
6:45 PM – Case Presentation and Discussion on High-risk APL: Challenges and Clinical Decisions
Michael A. Brister and Sheila De Young
7:10 PM – Case Presentation and Discussion on Low-Intensity vs. High-Intensity Treatment for Young, Fit AML Patients
Gina Keiffer and Tara Rakiewicz
7:35 PM – Case Presentation and Discussion on Menin Inhibitors in KMT2A Rearranged Relapsed AML
Sara Small and Christina Darwish
8:00 PM – Case Presentation and Discussion on CAR T-cell Therapy for ALL
Noelle Frey and Matthew Connor
8:25 PM – Panel discussion and wrap up
All Faculty
8:30 PM – Conclusion
Catherine Lai

Description

Interactive continuing medical education activity for healthcare professionals in Philadelphia, New Jersey, Delaware, and surrounding areas to discuss acute leukemia and myeloid malignancies updates and challenges in treatment.

Target Audience

This activity is intended for hematologists-oncologists, medical oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients with acute leukemia and myeloid malignancies. 

Educational Objectives

At the conclusion of this activity, participants will be better able to:
  • Explain the most recent data on novel treatment options in acute leukemias and myeloid malignancies
  • Discuss drug interactions with novel therapies and how to manage
  • Explain diagnostic and prognostic testing and challenges, relapse prevention and detection of measurable residual disease
  • Explain disparities and challenges in the diagnosis and treatment of acute leukemias and myeloid malignancies
  • Identify resources for patient education and support

Advisory Group

Catherine Lai, MD, MPH (Chair)
Hospital of the University of Pennsylvania
Philadelphia, PA
 
Katie Allen, CRNP
Hospital of the University of Pennsylvania
Philadelphia, PA
 
Alison Carulli, PharmD, BCOP
Hospital of the University of Pennsylvania
Philadelphia, PA
 
Margie Kasner, MD, MSCE
Sidney Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA
 
Grace Shyu, PA-C
Hospital of the University of Pennsylvania
Philadelphia, PA
 
Michael Styler, MD
Fox Chase Cancer Center
Temple University
Philadelphia, PA

Faculty

Catherine Lai, MD, MPH (Chair)
Hospital of the University of Pennsylvania
Philadelphia, PA
 

Michael A. Brister, MD
Cooper University Health Care 
Camden, NJ

Matthew Connor, MD
Hospital of the University of Pennsylvania 
Philadelphia, PA

Christina Darwish, MD
Fox Chase Cancer Center
Temple University
Philadelphia, PA

Sheila De Young, DO
Cooper University Health Care 
Camden, NJ

Noelle Frey, MD, MS
Hospital of the University of Pennsylvania
Philadelphia, PA

Gina Keiffer, MD
Sidney Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA
 
Ruby Nava-Ramos, MPH

The Leukemia & Lymphoma Society
Washington, DC

Tara Rakiewicz, MD
Sidney Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA
 

Sara Small, MD, PhD
Fox Chase Cancer Center
Temple University
Philadelphia, PA

 
 
This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute Inc, in collaboration with the Association of Cancer Care Centers™ (ACCC).

 

The Leukemia & Lymphoma Society thanks Autolus Therapeutics and Novartis Pharmaceuticals Corporation for their financial support.

 

For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: profeducation@LLS.org.

 

Follow LLS